Multiple drugs

Multiple drugs Reactions 1680, p242 - 2 Dec 2017 Various toxicities: 11 case report In a retrospective study, 11 patients (eight men and three women) aged 25 76 years were described, who developed Pneumocystis jiroveci pneumonia (eight patients), Pneumocystis jiroveci pneumonia with acute respiratory distress syndrome (one patient), and sepsis and multiple organ failure secondary to Pneumocystis jiroveci pneumonia (two patients) while receiving immunosuppressive therapy with ciclosporin [cyclosporine], mycophenolate mofetil and prednisolone (three patients), tacrolimus and prednisolone (one patient), ciclosporin, mycophenolate sodium and prednisolone (two patients), and tacrolimus, mycophenolate mofetil and prednisolone (five patients). Additionally, one of these 11 patients (a 25-year-old woman) developed cutaneous reaction during treatment with cotrimoxazole [trimethoprim/ sulfamethoxazole; not all dosages stated, routes and durations of treatments to reaction onsets not stated]. All the patients underwent heart transplantation. Following the heart transplantation, the patients started receiving immunosuppressive therapies with ciclosporin, mycophenolate mofetil and prednisolone (three patients), tacrolimus and prednisolone (one patient), ciclosporin, mycophenolate sodium and prednisolone (two patients), and tacrolimus, mycophenolate mofetil and prednisolone (five patients). Five patients (four men and one woman) also received cotrimoxazole as a prophylactic therapy for Pneumocystis jiroveci pneumonia. However, following the immunosuppresive therapies, the patients developed Pneumocystis jiroveci pneumonia (0.4 16.3 years following the heart transplantation). The patients were treated with cotrimoxazole (3.7 19.2 mg/kg/day) for a duration of 6 34 days. Additionally, four men received anidulafungin with cotrimoxazole, and one man received caspofungin with cotrimoxazole. One of these 11 patients (a 25-year-old female) also developed severe cutaneous reaction following treatment with cotrimoxazole, and was switched to primaquine and clindamycin, which eventually resolved. During the last follow up examination after receiving the treatment, eight patients remained alive, but one man died due to acute respiratory distress syndrome and two women died because of sepsis with multiple organ failure. Author comment: "In solid organ transplant recipients receiving standard immunosuppressive therapy, the incidence of Pneumocystis jiroveci pneumonia (PJP) is 5% 14%. . .A review of immunosuppressive agents indicated that the combination of tacrolimus, mycophenolate, and prednisolone was the most commonly prescribed." Lu Y-M, et al. Combination of Echinocandins and Trimethoprim/Sulfamethoxazole for the Treatment of Pneumocystis jiroveci Pneumonia After Heart Transplantation. Transplantation Proceedings 49: 1893-1898, No. 8, Oct 2017. Available from: URL: http://doi.org/10.1016/j.transproceed.2017.04.020 - Taiwan 803285091 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Multiple drugs

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/multiple-drugs-dC0BvIqNxY
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39173-2
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p242 - 2 Dec 2017 Various toxicities: 11 case report In a retrospective study, 11 patients (eight men and three women) aged 25 76 years were described, who developed Pneumocystis jiroveci pneumonia (eight patients), Pneumocystis jiroveci pneumonia with acute respiratory distress syndrome (one patient), and sepsis and multiple organ failure secondary to Pneumocystis jiroveci pneumonia (two patients) while receiving immunosuppressive therapy with ciclosporin [cyclosporine], mycophenolate mofetil and prednisolone (three patients), tacrolimus and prednisolone (one patient), ciclosporin, mycophenolate sodium and prednisolone (two patients), and tacrolimus, mycophenolate mofetil and prednisolone (five patients). Additionally, one of these 11 patients (a 25-year-old woman) developed cutaneous reaction during treatment with cotrimoxazole [trimethoprim/ sulfamethoxazole; not all dosages stated, routes and durations of treatments to reaction onsets not stated]. All the patients underwent heart transplantation. Following the heart transplantation, the patients started receiving immunosuppressive therapies with ciclosporin, mycophenolate mofetil and prednisolone (three patients), tacrolimus and prednisolone (one patient), ciclosporin, mycophenolate sodium and prednisolone (two patients), and tacrolimus, mycophenolate mofetil and prednisolone (five patients). Five patients (four men and one woman) also received cotrimoxazole as a prophylactic therapy for Pneumocystis jiroveci pneumonia. However, following the immunosuppresive therapies, the patients developed Pneumocystis jiroveci pneumonia (0.4 16.3 years following the heart transplantation). The patients were treated with cotrimoxazole (3.7 19.2 mg/kg/day) for a duration of 6 34 days. Additionally, four men received anidulafungin with cotrimoxazole, and one man received caspofungin with cotrimoxazole. One of these 11 patients (a 25-year-old female) also developed severe cutaneous reaction following treatment with cotrimoxazole, and was switched to primaquine and clindamycin, which eventually resolved. During the last follow up examination after receiving the treatment, eight patients remained alive, but one man died due to acute respiratory distress syndrome and two women died because of sepsis with multiple organ failure. Author comment: "In solid organ transplant recipients receiving standard immunosuppressive therapy, the incidence of Pneumocystis jiroveci pneumonia (PJP) is 5% 14%. . .A review of immunosuppressive agents indicated that the combination of tacrolimus, mycophenolate, and prednisolone was the most commonly prescribed." Lu Y-M, et al. Combination of Echinocandins and Trimethoprim/Sulfamethoxazole for the Treatment of Pneumocystis jiroveci Pneumonia After Heart Transplantation. Transplantation Proceedings 49: 1893-1898, No. 8, Oct 2017. Available from: URL: http://doi.org/10.1016/j.transproceed.2017.04.020 - Taiwan 803285091 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve Freelancer

DeepDyve Pro

Price
FREE
$49/month

$360/year
Save searches from
Google Scholar,
PubMed
Create lists to
organize your research
Export lists, citations
Read DeepDyve articles
Abstract access only
Unlimited access to over
18 million full-text articles
Print
20 pages/month
PDF Discount
20% off